Project Grant R43AG066271

This Project Grant award from the National Institute of General Medical Sciences (NIGMS), under the Biomedical Research and Research Training program (CFDA 93.859), provides $202,274 to develop an easy-to-use computer program for predicting the structure and degrading efficiency of proteolysis targeting chimeras (PROTACs). PROTACs are heterobifunctional molecules that induce the degradation of target proteins by recruiting them to E3 ubiquitin ligases. The awarded project aims to implement a...

This three-year, $760,000 project grant from the National Institute on Drug Abuse will support the development of novel therapeutic lead compounds for stimulant use disorder. Funded under the Drug Abuse and Addiction Research Programs (CFDA 93.279), the award to West Virginia University Research Corporation will focus on chemical synthesis innovations to produce analogs of illudalic acid, a potent and irreversible inhibitor of protein tyrosine phosphatase receptor type D (PTPRD). PTPRD has...

Jillion Therapeutics Inc. received a $399,483 Phase I Small Business Innovation Research (SBIR) Project Grant from the National Institute on Drug Abuse (NIDA) under the Drug Use and Addiction Research Programs (CFDA 93.279), awarded on May 15, 2025, with completion targeted for April 30, 2026. The company will leverage its proprietary DNA-Encoded Library (DEL) drug discovery platform combined with artificial intelligence to identify novel polypharmacological therapeutic compounds for substance...

This National Science Foundation (NSF) Technology, Innovation, and Partnerships (CFDA 47.084) Project Grant award of $275,000 to Om Therapeutics Inc. will support the development of a system to enable the rapid, scalable, and cost-effective discovery of new medicines using machine learning. The project aims to encapsulate proteins and small molecules in millions of miniaturized compartments to screen for interactions that could identify novel drug candidates. The key innovations include...

Federal Grant Award Summary Dark Matter Therapeutics, Inc. received a $798,828 Project Grant award from the National Institute on Drug Abuse (NIDA) under the Drug Use and Addiction Research Programs (CFDA 93.279) to develop an artificial intelligence platform for discovering novel small molecule therapeutics to treat Opioid Use Disorder (OUD). The award, obligated on May 1, 2025, with a completion date of April 30, 2026, supports the development and application of the M3.AI platform, which...

The U.S. National Science Foundation (NSF) awarded a $303,864 Phase I Small Business Innovation Research (SBIR) grant under the NSF Technology, Innovation, and Partnerships (CFDA 47.084) program to Core Biotherapeutics, Inc. (UEI N9FGZ15RQGJ4) located in Ladera Ranch, CA. The project aims to develop a platform for discovering therapeutic drug candidates that can modulate molecular networks driving diseases, with the potential to produce disease-modifying effects for neurodegenerative...

Federal Grant Award Summary Tango Biosciences Inc. received a $314,363 Project Grant award from the National Institute of General Medical Sciences under the Biomedical Research and Research Training program (CFDA 93.859), effective July 1, 2025, through July 2, 2026. The company is developing the Avidimer Platform, a novel molecular toolbox designed to accelerate proximity research and drug discovery by enabling the identification of small molecules and biologics that induce proximity between...

The National Science Foundation (NSF) awarded a $275,000 Project Grant under the NSF Technology, Innovation, and Partnerships (CFDA 47.084) program to Foragr Medicines, Inc. for a SBIR Phase I project titled "High-Throughput Platform for Small Molecule, In-Cell Targeting of Undruggable Proteins via their mRNAs". The project aims to develop a high-throughput drug discovery platform to identify small molecule drugs that can target the mRNA of hard-to-treat diseases, including...

Award Summary Yale University received a $460,740 Project Grant from the National Institute of General Medical Sciences under the Biomedical Research and Research Training program (CFDA 93.859), awarded August 1, 2025, with a completion date of July 31, 2030. The award supports research to develop novel quantitative experimental and computational methods for studying continuous phenotypic transitions in cellular states. The research employs proteolysis-targeting chimeras (PROTACs) as chemical...

Federal Grant Award Summary Nostopharma LLC received a $815,584 Project Grant award from the National Center for Advancing Translational Sciences (NCATS, CFDA 93.350) effective July 3, 2025, with completion targeted for June 30, 2027. The award funds a preclinical proof-of-concept study to develop locally administered, extended-release nanoparticle formulations containing arsenic trioxide (ATO), a Hedgehog pathway inhibitor, for treating Fibrodysplasia Ossificans Progressiva (FOP). FOP is an...